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in these stable patients, elevated levels of sCD40L did not predict CAD and were not
associated with a higher risk of clinical events (death, MI). In fact, a trend towards lower
sCD40L levels in CAD compared to non-CAD patients was observed. This novel interac-
tion of sCD40L with type of presentation raises interesting questions for CAD pathogene-
sis and prognosis and should be further evaluated.
1137-98 Impact of Combination Evidence-Based Medical 
Therapy on Mortality in Patients With Acute Coronary 
Syndromes
Debabrata Mukherjee, Kartik Giri, Jianming Fang, Stanley Chetcuti, Mauro Moscucci, 
Eva Kline-Rogers, Kim A. Eagle, University of Michigan, Ann Arbor, MI
Background: Antiplatelet drugs, beta-blockers, ACE inhibitors and lipid lowering agents
have proven efficacy in reducing mortality in patients with acute coronary syndromes.
However, the impact of the combination of these agents when used together on clinical
outcomes has not been studied before.
Methods Patients presenting with acute coronary syndromes between 01/99 and 03/02
were identified. Based on discharge use of evidence-based therapies, we created a com-
posite appropriateness score depending on the number of the drugs used divided by the
number of the drugs indicated for each patient. The impact of the composite score on 6-
month mortality was analyzed using a risk-adjusted logistic regression model.
Results: The odds ratio for death for all indicated medications used (appropriateness
level IV) vs. none of the indicated medications used (appropriateness level 0) was [0.13,
95% CI 0.04-0.38, p=0.0002]; similarly for appropriateness level III vs. level 0 was [0.15,
95% CI 0.05-0.45, p=0.0008]; for appropriateness level II vs. level 0 was [0.20, 95% CI
0.06-0.64, p=0.006] and for appropriateness level I vs. level 0 was [0.28, 95% CI 0.08-
1.01, p=0.051].
Conclusions: Use of combination evidence-based medical therapies was independently
and strongly associated with lower 6-month mortality in patients with acute coronary syn-
dromes. Such therapies, most of which are generic and inexpensive today, appear to
offer a marked survival advantage when compared to patients where such therapies are
omitted. 
1137-99 Clopidogrel in Unstable Angina Patients Who Would 
Have Been Excluded From Randomized Pivotal Trials
Laurent Payot, Jean Philippe Collet, Gilles Montalescot, Rémi Choussat, Jean philippe 
Metzger, Gérard Dobrinski, Daniel Thomas, Centre Hospitalier Universitaire Pitié-
Salpétrière (AP-HP), Paris, France
Objectives:
We describe the characteristics and examine the efficacy and safety of Clopidogrel in
unstable angina /non-ST-elevation myocardial infarction (UA/NSTEMI)patients who would
have not been eligible for the Cure trial.We compared this group to the patients fitting the
Cure criteria.
Background:
It is not known whether the benefit shown with clopidogrel in the selected population of
pivotal trials can be extended to the real world.
Methods and Results:
All patients with UA/NSTEMI were anticoagulated with subcutaneous enoxaparin associ-
ated with a double antiplatelet regimen including a loading aspirin and 300mg clopidogrel
as first line medical stabilization treatment. Among 517 consecutive patients, we identi-
fied 117 patients ( "EP" for excluded patients)who would have not been eligible.This EP
group was older,had a lower creatinine clearance, had more frequently a past-history of
CABG or a diagnosis of non-Q MI on admission in comparison with patients without any
of the exclusion criteria ("NEP"for non excluded patients). Moreover the EP had a lower
ejection fraction (48% vs 55%, p<0,001), a higher TIMI risk score (3.27%vs 2.80%,
p=0.0016), a longer hospitalisation duration (3.93 days ± 2.83 vs 3.11 days ± 1.64;
p<0.0001) and a higher rate of diabetes (31.6% vs 21.7%, p<0.05). The use of GPIIb/IIIa
inhibitors was similar in the two groups (41% vs 43%, p=NS). The EP group underwent
less frequently PCI than those of the NEP group (56% vs 68%,p=0.01). There was a non
significant trend for a higher rate of major bleeding at 30-day in the EP group (5.1% vs
2.7%,p=NS). The rate of major coronary events at 30 days (myocardial infarction and
death) was higher in the EP group (14.5% vs 4.5%, p =0.0013). When considering
severe renal failure (creatinine clearance<30 ml/min), there was still no significant differ-
ence in the rate of major bleeding (5.62 vs 2.24, p= 0.06), although the number of EP
rose up to 160.
Conclusion:
Patients who do not fit the enrolment criteria of Cure trials have higher risk baseline char-
acteristics for both bleedings and ischemic events. In these patients, the use of clopi-
dogrel was associated with a moderate and non significant increase of bleedings
compared to typical "CURE" patients.
1137-100 Five-Year Survival Data From the APRICOT Trials: Does 
Female Gender Really Portend Unfavorable Outcome?
Hendrik-Jan Dieker, Nick Clappers, Peter C. Kievit, Marc A. Brouwer, Paul J.P.C. van den 
Bergh, Wim R.M. Aengevaeren, Gerrit Veen, Freek W.A. Verheugt, University Medical 
Center St. Radboud, Nijmegen, The Netherlands
Background: Few studies have thoroughly addressed the unfavorable outcome of
women after acute MI, especially in the long-term; discussion remains with respect to the
impact of clinical and angiographic baseline differences. This is the scope of the current
5-year survival study.
Methods: Patients (n=452) had fibrinolysis (FL) for acute STEMI and an open infarct
artery at 24-hour angiography. Three-month follow-up (FU) angiography and 5-year clini-
cal FU (97%) were obtained.
Results: Of the 452 patients 75 (17%) were female. Women were older (59+11 vs. 56+9
yrs, p>0.01), more often known with hypertension (39% vs. 22%, p>0.01) and more often
smokers than men (73% vs. 63%, p=0.08). Single vessel disease was more frequent
among women: 69% vs. 54% (p=0.01). Baseline stenosis severity (QCA) was less
severe: 54+14 vs. 58+13 (p=0.04). The 3-month reocclusion rate was similar in men and
women (20% vs. 19%). 5-year survival did not differ (89% vs. 91%). Gender was not
independently associated with survival.
Conclusions: Survival 5 years after successful FL did not differ between men and
women, despite a less favorable clinical baseline profile. Women more often had single
vessel disease and less severe culprit lesions, but similar reocclusion rates. These find-
ings after successful FL challenge the often generalized association between gender and
outcome and warrant further exploration as to whether this relationship is primarily driven
by an association in the subset of patients after failed FL. 
1137-101 Elevated Parathyroid Hormone Is an Important Predictor 
of Coronary Events in Patients With Chronic 
Hemodialysis
Takashi Kubo, Takuzo Hano, Masahiro Obana, Toshio Imanishi, Akira Baba, Kazushi 
Tsuda, Yoshiaki Tomobuchi, Mikio Arita, Ichiro Nishio, Wakayama Medical University, 
Wakayama, Japan
BACKGROUND: Secondary hyperparathyroidism is prevalent among patients with
chronic hemodialysis and influences the calcium metabolism. Excess of parathyroid hor-
mone (PTH) may play an important role in the development of coronary calcification and
atheroscrelosis. The aim of this study was to evaluate whether serum levels of PTH can
predict risk for future coronary events.
METHODS: A consecutive series of 104 patients with chronic hemodialysis undergoing
coronary angiography were enrolled in this study. We measured baseline serum intact
PTH levels and long-term clinical outcomes were obtained. The incidence of coronary
events (stable angina, unstable angina and acute myocardial infarction) due to new coro-
nary lesions confirmed by angiography was compared with the serum intact PTH levels.
RESULTS: The prevalence of secondary hyperparathyroidism (intact PTH > or = 65 pg/
ml, 311 +/- 284.1 pg/ml, mean +/- SD) was 60 of 104 patients (58%). During 3-year fol-
low-up, the incidence of coronary events associated with new coronary lesions was sig-
nificantly higher in patients with hyperparathyroidism than that in patients with normal
PTH (27% vs. 5%, p<0.001). Univariate Cox regression analysis demonstrated that dia-
betes (HR=10.4, 95% CI=2.4 to 45.2, p=0.002), hyperparathyroidism (HR=7.8, 95%
CI=1.8 to 34.3, p=0.006), obesity (HR=3.3, 95% CI=1.3 to 8.3, p=0.013) and hyperlipi-
demia (HR=2.6, 95% CI=1.1 to 6.6, p=0.042) were significant predictors of the develop-
ing coronary events, however, age, sex, duration of hemodialysis and other conventional
risk factors were not. In a multivariate analysis, hyperparathyroidism remained an inde-
pendent predictor of developing coronary events (HR=5.5, 95% CI=1.2 to 25.5, p=0.028).
CONCLUSION: In patients with chronic hemodialysis, the elevated PTH was an indepen-
dent and strong predictor of coronary events after adjusting for conventional risk factors.
